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Outcome (N5 30) (N5 30) p value
1 yr Non-Relapse
Mortality
8% (95% CI, 2-27) 41% (95% CI, 23-61) 0.03
2 yr Relapse
Mortality
25% (95% CI, 15-40) 20% (95% CI, 11-35) 0.9
2 yr Overall
Survival
63% (95% CI, 43-91) 38% (95% CI, 23-63) 0.034
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First recommended alternative donor to human-leucocyte antigen
(HLA) matched sibling for hematopoietic stem cell transplantation
(HSCT) is HLA 8/8 allele matched unrelated donor. There still
are a number of patients who need to find second alternative donor.
Recent advances in unrelated cord blood transplantation (UCBT)
enabled patients to increase the choices for second alternative do-
nor/stem cell source.
We made a HLA mismatched-locus-specific comparison of the
outcomes of unrelated cord blood and bone marrow recipients.
1196 HLA one or two high resolution mismatched (class I one-allele
mismatched, 491, class II one-allele mismatched, 314, two-allele
mismatched, 391) BM recipients and 418 HLA-A, -B high resolu-
tion, and –DRB1 low resolution zero to two antigen mismatched
(matched, 25, one-antigen mismatched, 105, two-antigen mis-
matched, 288) CB recipients were analyzed. Subjects were limited
to adult patients whose age was 16 years or older at the time of trans-
plant who received first stem cell transplantation with myeloablative
conditioning for hematological malignancy.
With adjusted analyses, HLA one- (relative risk [RR]5 1.00, 95%
confidence interval [CI], 0.73-1.37, P5 0.99) or two- (HR5 0.97,
95%CI, 0.76-1.22, P5 0.77) antigen mismatched UCBT and
HLA-C one-allele mismatched UBMT (RR5 0.96, 95%CI, 0.77-
1.20, P5 0.74) showed similar overall mortality compared to
HLA-DRB1 one-allele mismatched UBMT. UCBT showed higher
relapse rate (RR5 2.47 for matched, RR5 1.93 for one-antigen
mismatched, RR5 1.53 for two-antigen mismatched, P5 0.013,
0.0051, 0.025, respectively), lower risk of acute GVHD (RR5 0.58
for matched, RR5 0.60 for one-antigen mismatched, RR5 0.66
for two-antigen mismatched, P5 0.15, 0.011, 0.003, respectively),
and inferior neutrophil recovery (RR5 0.69 for matched,
RR5 0.51 for one-antigen mismatched, RR5 0.48 for two-antigen
mismatched, P5 0.062,\0.0001,\0.0001, respectively) compared
to HLA-DRB1 one-allele mismatched UBMTHLA zero to two an-
tigen mismatched UCBT is a favorable second alternative donor/
stem cell source with similar survival outcome with HLA-DRB1
one-allele mismatched UBMT, the current recommended second
alternative donor. However, risk of relapse was higher among
UCBT, that it should be carefully decided according to disease
and clinical status of the recipients.5
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Regulatory T cells (Treg) are important for maintaining tolerance
after bone marrow transplantation (BMT) in experimental models.
However, the relationship between Treg and acute graft-versus-
host disease (GVHD) in BMT recipients is not well established.
We prospectively analyzed Treg frequency in 215 BMT patients
(125 allogeneic, 90 autologous). Fresh blood samples were acquired
within 24 hours of GVHD onset and at equivalent time points in
patients without GVHD. We measured by flow cytometry the
frequency of CD4+CD25hiFOXP3+ cells within total lymphocytes.
There were no significant differences between patients with and
without GVHD for age, conditioning intensity, and day of sample
acquisition. Recipients from unrelated or HLA-mismatched donors
were overrepresented in the GVHD group. Autologous (N5 90)
and allogeneic BMT patients without GVHD (N5 65) had the
same mean Treg frequency (1.09%60.10 vs. 1.09%60.11,
p5 0.54), showing that the use of calcineurin inhibitors may not
affect Treg reconstitution. Patients with GVHD (N5 60) had a T
reg frequency that was 40% less (0.66%60.07, p\0.001) than those
without GVHD. Frequencies of Tregs were significantly reduced in
patients with $ grade II GVHD at onset compared to patients
without GVHD (p\0.001). The area under the Receiver Operating
Characteristic curve for Treg frequency as an independent
biomarker of GVHD was 0.69. Treg frequency also correlated
with the eventual maximum overall grade of GVHD (r 5 -0.33;
p\0.001), suggesting prognostic value for this measurement.
Therefore, we evaluated whether Treg frequency would correlate
with outcomes by dividing the 60 patients with GVHD according
to their median Treg frequency (0.5%). Patients with low Treg fre-
quency had a significantly greater non relapse mortality (NRM)
(41% vs. 8%, p5 0.03) than patients with high Treg frequency,
which resulted in an inferior survival at two years (38% vs. 63%,
p5 0.03)(Table 1). GVHD accounted for the majority of NRM in
the low Treg frequency group. Relapse mortality was similar
between groups (p5 0.9)(Table1). This difference in survival
remained significant after adjusting for other important prognosticS155
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sity (p5 0.05). In this large set, frequency of CD4+CD25hiFOXP3+
Tregs at onset of GVHD correlates with GVHD severity, eventual
maximumGVHDgrade andNRM. Treg frequency thus has impor-
tant diagnostic and prognostic value as a biomarker for acute
GVHD.6
A PROSPECTIVE, RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF
APREPITANT VS. PLACEBO PLUS ORAL ONDANSETRON ANDDEXAMETH-
ASONE FOR THE PREVENTION OF NAUSEA AND VOMITING (N/V) ASSO-
CIATED WITH HIGHLY EMETOGENIC PREPARATIVE REGIMENS PRIOR
TO HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
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Delayed N/V is often a major toxicity in patients undergoing
ablative preparative regimens prior to HSCT. Aprepitant (APR),
an NK-1 antagonist is effective in preventing delayed N/V with
moderate and highly emetogenic standard dose chemotherapy and
thus may be of value in the transplant setting. However APR inter-
acts with cytochrome P450 involved in the bioactivation of high
dose cyclophosphamide, and may interfere with etoposide pharma-
cokinetics; thus may impact regimen related toxicity (RRT) and sur-
vival post transplant. While several small Phase II studies have
suggested the benefit of APR in HSCT, no prospective comparisons
have been reported.We performed a randomized (1:1) blinded Phase
III trial to determine the safety and efficacy of APR for N/V due to
ablative preparative regimens. Patients received either placebo
(PBO) or oral APR 125 mg PO day 1 then 80 mg daily for all days
of the preparative regimen and for 3 days after it ended, in addition
to oral ondansetron 8 mg PO q 8hrs + IV dexamethasone (DEX)
daily during and for 1 day after the preparative regimen. Due to
a known drug interaction between APR and dexamethasone, blinded
DEXdoses were used (10 mg -placebo; 7.5 mg – APR). Patients were
stratified based on gender; those with heavy ETOH use were ex-cluded. Clinical evaluations were performed daily with the primary
endpoint being a CR, defined as: no emesis and no or mild nausea
[less than grade (gr) 3 using CTC 2.0 criteria]. Other endpoints in-
cluded; major response (MR): 1 episode of emesis or moderate nau-
sea; minor response (mR): 2–4 episodes of emesis; and failure (F):.4
episodes of emesis. Major efficacy (ME)5CR +MR. Nausea was
measured on a 100 mm visual analog scale (VAS) with 05 no nausea.
Safety analyses performed included grade 3-5 toxicities, time to en-
graftment, PFS andOS. The 181 randomized patients were balanced
with respect to age, weight, donor source and h/o N/V with prior
chemotherapy. Patients received one of 5 ablative prep regimens:
CY/TBI/VP16 (36), CY/TBI (79), IV BU/CY (19), PO BU/CY
(34), and BCV(16). Two pts never proceeded to transplant so only
179 pts are eligible for analysis. Efficacy: see Table. Days to engraft-
ment; grade 3-5 RRT, PFS and OS were identical between the two
groups.
Conclusions: When used up to 10 days with ablative HSCT regi-
mens, aprepitant significantly improved N/V with a major impact
on emesis rates. It appears safe for this indication with no impact
on WBC and PLT engraftment or PFS/OS.
Ondansetron/dexamethasone 1/- Aprepitant for BMT regi-
men related N/V: Results
Aprepitant Placebo p value% ptts with no emesis during
study period73.3 22.5 \0.001% pts with CR: no emesis1\ gr 3
nausea during entire period48.9 14.6 \0.001% of days no emesis and
\ gr 3 nasuea, all pts81.9 65.8 \0.001Ave VAS scores 16.5 16.9 0.892
Composite MR 16.0 16.9 0.011
Composite mR 2.0 10.3 \0.001
Composite F 0.1 2.2 0.001
Composite ME 97.9 87.4 \0.001
